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Background: Treatment and outcomes of patients with HER2-positive (HER2þ) metastatic breast cancer
(MBC) have dramatically improved over the past 20 years. This work evaluated treatment patterns and
outcomes according to age.
Methods: Women who initiated a treatment for HER2þ MBC between 2008 and 2016 in one of the 18
French comprehensive centers part of the ESME programwere included. Objectives were the description
of first-line treatment patterns, overall survival (OS), first-line progression-free survival (PFS), and
prognostic factors among patients aged 70 years or more (70þ), or less than 70 (<70).ncer medicine, Institut Gustave Roussy, 114 Rue Edouard Vaillant, 94805, Villejuif, France.
(S. Delaloge).
Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).




HER2Results: Of 4045 women diagnosed with an HER2þ MBC, 814 (20%) were 70þ. Standard first-line
treatment (chemotherapy combined with an anti-HER2 therapy) was prescribed in 65% of 70þ versus
89% of <70 patients (p < 0.01). Median OS was 49.2 (95% CI, 47.1e52.4), 35.3 (95% CI, 31.5e37.0) and 54.2
months (95% CI, 50.8e55.7) in the whole population, in patients 70þ and <70, respectively. Corre-
sponding median PFS1 were 12.8 (95% CI, 12.3e13.3), 11.1 (95% CI, 10.0e12.3) and 13.2 months (95% CI,
12.7e13.9), respectively. In 70þ women, initiation of non-standard first-line treatment had an inde-
pendent detrimental time-varying effect on both OS and PFS (HR on OS at 1 year: chemotherapy without
anti-HER2 2.79 [95% CI: 2.05e3.79]; endocrine therapy and/or anti-HER2 1.96 [95% CI: 1.43e2.69]).
Conclusions: In this large retrospective real-life database, older women with HER2þ MBC received
standard first-line treatment less frequently than younger ones. This was independently associated with
a worse outcome, but confounding factors and usual selection biases cannot be ruled out.
© 2021 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Aging is the most important risk factor for developing cancer.
Breast cancer (BC) is not an exception to the rule, with a median age
of 62 years at diagnosis, 40e50% being diagnosed at age 70 or older
in western countries [1]. Human epidermal growth factor receptor
2-positive (HER2þ) BC, defined by an overexpression of HER2 or a
HER2 gene amplification accounts for 20% of metastatic BC (MBC)
and 10% of older patients with cancer [2,3]. Since the early 2000s,
many anti-HER2 therapies have revolutionized the prognosis of
HER2þ MBC patients, from trastuzumab added to first-line
chemotherapy [4] to the more recent dual anti-HER2 blockade
adding a second antibody, pertuzumab, increasing further overall
survival (OS) by 16 months [5]. Both lapatinib and T-DM1
contributed also to the global improvement of HER2þ MBC prog-
nosis [6e8], and the list of anti-HER2 treatments has been updated
very recently with tucatinib and new antibody-drug conjugates as
DS-8201 [9,10]. Most of these strategies show a good safety profile,
although data available are sparse in older patients [11e13]. Indeed,
older patients remain underrepresented in clinical trials. Moreover,
when enrolled, they do not reflect those seen in routine oncology
practice because of restrictive eligibility criteria [14,15]. Older pa-
tients also show poorer outcome compared with younger ones,
evenwhen adjusted for classical prognostic tumours characteristics
[16].
The American Society of Clinical Oncology supports high-quality
observational studies as complementary to randomized controlled
trials (RCTs) to improve evidence-based practice [17]. Unveiling
information absent in highly selected settings as most RCTs,
observational data can help generating hypotheses, especially for
populations underrepresented in RCTs, such as older patients.
Observational data however require cautious interpretation to
address the usual confounding factors and lack of control [18].
Large observational real-life datasets, such as the longitudinal
Epidemiology Strategy and Medical Economics (ESME) MBC data-
base, represent an opportunity to investigate treatment real-life
patterns and outcomes for distinct subgroups of MBC patients.
RCT data on anti-HER2 treatments and outcome in older patients
with MBC being limited, objectives were to describe treatment
patterns, overall survival (OS) and first-line progression-free sur-
vival (PFS) in womenwith HER2þMBC aged 70 and older (70þ), as
compared to younger ones (<70) over the last decade, based on the
ESME real-life database [19].
2. Patients and methods
2.1. Overall study design
The French ESME MBC database (NCT03275311) is a national139multicenter observational program. It collects real world data from
all consecutive MBC patients aged 18 years who initiated their
care at the time of MBC diagnosis, in the network of 18 French
comprehensive cancer centers, starting from 2008 [2,20]. Patients
referred “secondary” after they have initiated their first-line
treatment elsewhere are not eligible for the cohort. Data are
updated annually and include latest patients' and tumours’ char-
acteristics, outcomes and treatment patterns. ESME does not collect
data on toxicity or patient reported outcomes.
The present analysis was approved by an independent ethics
committee (Comite De Protection Des Personnes Sud-Est II- 2015-
79). No formal dedicated informed consent was required but all
patients had approved the re-use of their electronically recorded
data. In compliance with French regulations, the ESME MBC data-
base was authorized by the French data protection authority
(Registration ID 1704113 and authorization NDE-2013.-117).
Moreover, in compliance with the applicable European regulations,
a complementary authorization was obtained on 14-Oct-2019
regarding the ESME research Data Warehouse.2.2. Patients selection
For the present study, all women in the ESME database who had
a metastatic breast cancer classified as “HER2-positive” (HER2þ)
were selected. As described before, HER2 and HR status are derived
from existing results about metastatic tissue sampling where
available, or, if not available, from last sampling on early disease [8].
HER2þ means that the latest available sample of the tumor has a
HER2 immunohistochemical score (IHC) 3þ, or 2þ with a positive
chromogenic/fluorescence in situ hybridization (CISH/FISH),
whether hormone receptor positive or negative.2.3. Definitions and endpoints
Tumours were defined as hormone receptors (HR) positive if ER
and/or PgR expression was >10% by IHC. Metastases-free interval
(MFI) was defined as the time between initial diagnosis and met-
astatic relapse, and categorized in three groups (6, 7e24, >24
months). First-line treatment was categorized as anti-HER2 ther-
apy-based [combined with either chemotherapy (defined as
“standard” 1st line treatment), or endocrine therapy, or their
combination] or not anti-HER2 therapy-based (i.e. chemotherapy
alone or endocrine therapy alone or their combination). The size of
the treating centre was categorized according to the number of
patients included in the ESME cohort (<700, 700e1399, 1400
patients). OS and PFS were defined as the delay between the date of
diagnosis of MBC and the date of death (any cause), or the date of
disease progression or death (any cause), respectively.
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Qualitative variables were described using frequency, percent-
age and 95% confidence interval (95%CI) (binomial law). They were
compared using a Chi2 test or a Fisher's exact test whenever
appropriate. Quantitative variables were described using mean and
standard deviations if the normality assumption was satisfied;
otherwise non-parametric statistics (median, range, quartiles) were
reported and compared using non-parametric Wilcoxon tests.
Median follow up was estimated using the reverse KaplaneMeier
estimator [21]. Survival times were described using the Kaplan-
Meier method and the median survival times and rates with 95%
CI were reported.
Regarding prognostic factors for time-to-event endpoints, in-
dependent analyses were carried out in the whole population, in
the older one (70þ) and in the younger one (<70). Univariate an-
alyses were first performed using Cox's proportional hazards (PH)
models. Variables significant at the 15%-level were fitted in multi-
variable models with final significance level set at 5%. The strength
of the association was estimated using the hazard ratio (HR) re-
ported with 95%CI. Prognostic factors investigated included: age at
diagnosis of metastasis (<70 vs 70þ for the analysis in the whole
population, continuously for the analysis per age group); tumour
hormonal receptor status (ERþ and/or PgR þ vs ER- and PgR-);
number of metastatic sites (1, 2, 3 or more) at diagnosis of metas-
tasis; visceral metastases at diagnosis of metastasis; de novo met-
astatic disease; MFI; choice of first-line treatment; size of the
treating centre. Baseline performance status (PS) and body mass
index (BMI) were not considered because of missing data exceeding
30%. The hypothesis of proportional hazards was assessed. When
this assumption was not verified, variables were included in the
Cox model using an interaction with time in order to provide un-
biased estimations.
All analyses were conducted with SAS software, version 9.4 (SAS
institute Inc., Cary NC, USA).
3. Results
3.1. Patients, tumours and first-line treatments characteristics
Of the 22463 patients available in the ESME MBC database andFig. 1. Study fl
140diagnosed between January 2008 and December 2016, 4045 (18.0%)
had an HER2þMBC, 814 of them (20.1%) being 70þ (Fig. 1). Median
age in the whole population, in the 70þ and <70 groups was 57
(range: [20e93]), 77 (range: [70e93]) and 53 (range: [20e69])
years, respectively. Among older patients, 524 (64.4%) were 70e79,
274 (33.7%) 80e89, and 16 (2%) 90 years old and over. Additional
patients and tumours’ characteristics are reported in Table 1.
Compared with women <70, older women had more often ERþ
and/or PgR þ disease (68.8% versus 63.0%, p ¼ 0.01).
First line treatments received are described in Table 2. The dis-
tribution of standard first-line treatment (chemotherapy combined
with an anti-HER2 treatment) was different according to the age
group (p < 0.01). Younger women received standard first-line
treatment more often than older women (89.1% vs 65.0%). They
also overall received anti-HER2 therapy (alone or in combination)
more often than women aged 70þ (92.3% vs 76.5%).
3.2. Overall survival and first-line progression free survival by age
category
With a median follow up of 53.4 months (95% CI, 50.9e55.4),
2049 patients (50.7%) were alive at data cut off. Median overall
survival was 49.2 months (95% CI, 47.1e52.4) in the whole cohort;
35.3 months (95% CI, 31.5e37.0) and 54.2 months (95% CI,
50.8e55.7) among women aged 70þ and <70, respectively (Fig. 2).
Corresponding results for PFS were 12.8 (95% CI, 12.3e13.3), 11.1
(95% CI, 10.0e12.3) and 13.2 months (95% CI, 12.7e13.9), respec-
tively (see Fig. 3).
3.3. Multivariate analyses
Table 3 describes the multivariate analysis of factors associated
with OS in the different groups of patients. Within the whole
cohort, this analysis retrieved classical prognostic factors associated
with shorter OS, including increasing age (HR ¼ 1.55; 95% CI,
1.38e1.73), higher number of metastatic sites (for modality 3 or
more sites, HR ¼ 2.10; 95% CI, 1.85e2.39), 6e24 months MFI
(HR ¼ 2.58; 95% CI, 2.25e2.95), presence of visceral metastases
(HR ¼ 2.67 at one year; 95% CI, 2.10e3.38). Longer OS was associ-
ated with positive hormone receptors (HR ¼ 0.63 at one year; 95%
CI, 0.56e0.71) and centers with a higher patient load (for 1400 orowchart.
Table 1
Characteristics of the patients.
Population (N) All (4045) 70þ (814) <70 (3231)
Patients characteristics
Median age at diagnosis (years) (Q1;Q3) 57 (47e67) 77 (73e82) 53 (45e60)
PS at MBC diagnosis
0 723 (17.9%) 67 (8.2%) 656 (20.3)
1 607 (15.0%) 123 (15.1%) 484 (15.0%)
2 175 (4.3%) 53 (6.5%) 122 (3.8%)
3 66 (1.6%) 18 (2.2%) 48 (1.5%)
4 10 (0.2%) 3 (0.4%) 7 (0.2%)
Missing 2464 (60.9%) 550 (67.6%) 1914 (59.2%)
BMI, median (Q1;Q3) 24.7 (21.6; 28.7) 25.2 (22.2; 29.3) 24.6 (21.5; 28.6)
Missing 1349 (33.3%) 319 (39.2%) 1030 (31.9%)
Tumours characteristics
Histological type (primary tumor)
IDC 3319 (82.1%) 633 (77.8%) 2686 (83.1%)
ILC 226 (5.6%) 69 (8.5%) 157 (4.9%)
IDC þ ILC 36 (0.9%) 9 (1.1%) 27 (0.8%)
Breast cancer origin 17 (0.4%) 2 (0.2%) 15 (0.5%)
Other 399 (9.9%) 89 (10.9%) 310 (9.6%)
Missing 48 (1.2%) 12 (1.5%) 36 (1.1%)
Histological grade (primary tumor)
Grade I 179 (4.4%) 49 (6.0%) 130 (4.0%)
Grade II 1629 (40.3%) 328 (40.3%) 1301 (40.3%)
Grade III 1589 (39.3%) 288 (35.4%) 1301 (40.3%)
Missing (Not determined, not available or not done) 648 (16.0%) 149 (18.3%) 499 (15.5%)
ER/PgR status
ER þ and/or PgR þ (>10%) 2594 (64.1%) 560 (68.8%) 2034 (63.0%)
ER- and PgR- 1414 (35.0%) 247(30.3%) 1167 (36.1%)
Undetermined 37 (0.9%) 7 (0.9%) 30 (0.9%)
MFI (months)
 6 (de novo MBC) 1626 (40.2%) 311 (38.2%) 1315 (40.7%)
]6e24 562 (13.9%) 104 (12.8%) 458 (14.2%)
>24 1850 (45.7%) 398 (48.9%) 1452 (44.9%)
Missing 7 (0.2%) 1 (0.1%) 6 (0.2%)
Number of metastatic sites at diagnosis
1 2099 (51.9%) 429 (52.7%) 1670 (51.7%)
2 1045 (25.8%) 211 (25.9%) 834 (25.8%)
 3 866 (21.4%) 170 (20.9%) 696 (21.5%)
Missing 35 (0.9%) 4 (0.5%) 31 (1.0%)
Presence of visceral disease at diagnosis
Yes 2606 (64.4%) 510 (62.7%) 2096 (64.9%)
No 1404 (34.7%) 300 (36.9%) 1104 (34.2%)
Missing 35 (0.9%) 4 (0.5%) 31 (1.0%)
Brain metastases at diagnosis
Yes 591 (14.6%) 92 (11.3%) 499 (15.4%)
No 3454 (85.4%) 722 (88.7%) 2732 (84.6%)
ILC: Invasive lobular carcinoma; FISH: Fluorescence in situ hybridization; CISH: Chromogenic in situ hybridization; ER: Estrogen receptor; PgR: Progesterone receptor; MBC:
Metastatic breast cancer; MFI: Metastasis free interval; NA: Not applicable.
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ceptors’ effect decreased over time, disappearing at 5 years. On the
opposite, the detrimental effect of visceral involvement increased
over time. Finally, as compared to standard first-line treatment
(chemotherapy combined with anti-HER2 therapy), non-standard
treatments were associated with an increased risk of deathTable 2
First-line treatment characteristics.
All (N ¼ 4045)
First-line treatment
Anti-HER2 therapy þ chemotherapy 3409 (84.3%)
Chemotherapy without anti Her2 222 (5.5%)
Anti-HER2 þ endocrine therapy 113 (2.8%)
Anti-HER2 therapy alone 85 (2.1%)
Endocrine therapy alone 117 (2.9%)
Missing 99 (2.4%)
Center size (number of patients/site)
< 700 202 (5.0%)
700e1399 2865 (70.8%)
1400 978 (24.2%)
141during the first years.
In the 70þ group, same trends were reported for most variables,
although with no time-varying effect for hormone receptor status
(HR ¼ 0.77; 95% CI, 0.62e0.95) and no impact of the size of the
treating centre. Increased age was associated with shorter OS
(HR ¼ 1.05; 95% CI, 1.03e1.07).Women 70þ (N ¼ 814) Women <70 (N ¼ 3231)
529 (65.0%) 2880 (89.1%)
68 (8.4%) 154 (4.8%)
63 (7.7%) 50 (1.5%)
31 (3.8%) 54 (1.7%)
79 (9.7%) 38 (1.2%)
44 (5.4%) 55 (1.7%)
31 (3.8%) 171 (5.3%)
599 (73.6%) 2266 (70.1%)
184 (22.6%) 794 (24.6%)
Fig. 2. OS in the whole study population and in the 70þ and <70 groups.
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whole population.
Table 4 describes the multivariate analysis for PFS. In the whole
population, independent prognostic factors for shorter PFS were
similar to those for OS. As compared to chemotherapy with anti-
HER2, both chemotherapy without anti-HER2 and treatment
without chemotherapy/anti-HER2 were associated with an
increased risk of progression over the first 3 years: HR ¼ 1.93 [95%
CI: 1.67e2.23] and HR ¼ 1.75 [95%CI: 1.51e2.03] at 1 year,
respectively.
In the 70þ group, same trends were observed for most variables.
No association was found with the size of the treating centre. Older
age was associated with shorter PFS (HR ¼ 1.03; 95% CI, 1.01e1.04).
Compared with chemotherapyþ anti-HER2 therapy, chemotherapy
alone had a deleterious non time-dependent effect on PFSFig. 3. First-line PFS in the whole study pop
142(HR ¼ 1.54 [95% CI: 1.18e2.02]), while treatment without chemo-
therapy had no real impact (HR ¼ 0.86 [95% CI: 0.70e1.05]).4. Discussion
To our knowledge, this report describes the largest real-life
cohort of women aged 70 or older with HER2þ MBC treated with
recent anti-HER2 therapies. Older patients being largely under-
represented in clinical trials, including those investigating anti-
HER2 therapies, very few data are available for this subpopulation
[19,22]. For example, CLEOPATRA included only 126 patients aged
65 years or older, with a median age of 69 years [13]. Moreover, of
808 patients enrolled, only 19 were aged 75 or older. With striking
numbers, we report on 814women 70 years or older, with amedian
age of 77 years, more representative of daily clinical practice.ulation and in the 70þ and <70 groups.
Table 3
Prognostic factors of overall survival in metastatic breast cancer patients in the ESME real-life database according to age.
All women 70þ <70
HR 95% CI p HR 95% CI p HR 95% CI p
Age (reference: < 70)
70
1.55 [1.38; 1.73] <0.01 NA NA
Age (continuous variable) NA 1.05 [1.03; 1.07] <0.01 1.01 [1.00; 1.01] 0.05
Number of metastatic sites at metastatic diagnosis (reference: 1 site) <0.01 <0.01
2 sites 1.32 [1.18; 1.49] 1.29 [1.01; 1.65] 1.34 [1.17; 1.53]
3 sites or more 2.10 [1.85; 2.39] <0.01 1.87 [1.43; 2.45] 2.17 [1.88; 2.51]
Visceral metastatic disease (reference: none) (*) <0.01 <0.01 <0.01
Time-varying effect:
Estimated HR at 1 year 2.67 [2.10; 3.38] 1.91 [1.21; 3.03] 3.11 [2.33; 4.14]
Estimated HR at 3 years 3.89 [3.07; 4.94] 2.48 [1.56; 3.92] 4.75 [3.56; 6.32]
Estimated HR at 5 years 5.68 [4.47; 7.20] 3.20 [2.02; 5.07] 7.24 [5.44; 9.65]
ER/PgR status (reference: both ER- and PgR-) <0.01 0.02 <0.01
If no time-varying effect, estimated average HR
Positive ER or positive PgR NA NA 0.77 [0.62; 0.95] NA
Undetermined ER/PgR status NA NA 1.67 [0.68; 0.95] NA
If time-varying effect, estimated HR at 1 year
Positive ER and/or PgR 0.63 [0.56; 0.71] NA 0.60 [0.52; 0.68]
Undetermined ER/PgR status 0.54 [0.32; 0.91] NA 0.45 [0.24; 0.83]
If time-varying effect, estimated HR at 3 years
Positive ER and/or PgR 0.79 [0.71; 0.89] NA 0.76 [0.67; 0.87]
Undetermined ER/PgR status 0.68 [0.40; 1.14] NA 0.57 [0.31; 1.06]
If time-varying effect, estimated HR at 5 years
Positive ER and/or PgR 1.00 [0.89; 1.12] NA 0.97 [0.85; 1.12]
Undetermined ER/PgR status 0.85 [0.50; 1.43] NA 0.73 [0.39; 1.36]
First-line treatment (reference: chemotherapy þ anti-HER2 therapy) 0.01 <0.01
If time-varying effect, estimated HR at 1 year
Chemotherapy without anti-HER2 therapy (±endocrine therapy) 3.40 [2.86; 4.05] 2.79 [2.05; 3.79] 3.77 [3.04; 4.66]
Anti-HER2 therapy alone or endocrine therapy alone or both 2.26 [1.80; 2.84] 1.96 [1.43; 2.69] 1.24 [0.78; 1.96]
If time-varying effect, estimated HR at 3 years
Chemotherapy without anti-HER2 therapy (±endocrine therapy) 2.00 [1.68; 2.38] 2.04 [1.50; 2.78] 2.11 [1.40; 2.61]
Anti-HER2 therapy alone or endocrine therapy alone or both 1.33 [1.05; 1.67] 1.44 [1.04; 1.97] 0.69 [0.43; 1.10]
If time-varying effect, estimated HR at 5 years <0.01
Chemotherapy without anti-HER2 therapy (±endocrine therapy) 1.17 [0.99; 1.40] 1.49 [1.10; 2.03] 1.18 [0.95; 1.46]
Anti-HER2 therapy alone or endocrine therapy alone or both 0.78 [0.62; 0.98] 1.05 [0.77; 1.45] 0.39 [0.24; 0.61]
MFI (months) (reference: < 6 months) 0.05 <0.01
6e24 months 2.58 [2.25; 2.95] 1.42 [1.05; 1.92] 3.06 [2.62; 3.58]
24 months and more 1.37 [1.24; 1.52] <0.01 1.01 [0.82; 1.26] 1.52 [1.35; 1.71]
Center size (number of patients/site) (reference: less than 700 patients) <0.01 <0.01
700 to 1399 patients 0.87 [0.71; 1.06] NS 0.91 [0.73; 1.13]




MFI: Metastasis free interval.
NS: Not significant.
NA: Not applicable.
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patients 70þ received anti-HER2 treatment with chemotherapy,
defined as standard first-line treatment, compared with 89.1% of
those <70 (global statistical test of first-line treatment distribution,
p < 0.01). Older patients may have impaired cardiac function,
limiting the prescription of anti-HER2 treatments and chemo-
therapy combinations. Increased toxicity is also feared, even in the
absence of such condition [23,24]. Our results suggest that these
differences in treatment choice may have an impact on the
outcome of older patients. Indeed, both PFS and OS in the 70þ
group were significantly lower than those in patients <70 with
median survival of 11.1months (95% CI,10.0e12.3) and 35.3months
(95% CI, 31.5e37.0) versus 13.2 months (95% CI, 12.7e13.9) and 49.2
months (95% CI, 47.1e52.4), respectively. After adjustment for
tumour characteristics, this effect of different treatment choices on
OS seemed to be present early, at 12 and 36 months, declining later
at 60 months. Of note, 11.5% of women 70þ received anti-HER2143alone or with endocrine therapy vs 3.2% in patients <70, stressing
the high interest for chemo-free combinations or combinations
with milder chemotherapy in the older population, as supported by
the recommendations by the Societe Internationale d’Oncogeriatrie
(SIOG) [19]. Moreover, although anti-HER2 alone or with endocrine
therapy had a detrimental effect on OS compared with standard
treatment, outcome was still better than chemotherapy alone.
As previously described, misestimating women's capacity and
remaining life expectancy may have contributed to undertreat-
ment, resulting in worse outcomes in older patients. However,
some older patients with cancer have many competing risks of
death due to multimorbidities. These should be carefully assessed
before treatment decision, especially because older persons may
develop more often important side effects, related to changes in
pharmacodynamic parameters, polypharmacy and underlying
frailty [25]. As advocated by SIOG, treatment of BC in older patients
should not be based on chronological age alone [26]. Screening for
Table 4
Prognostic factors of progression-free survival in metastatic breast cancer patients in the ESME real-life database according to age.
All women 70þ <70
HR 95% CI p HR 95% CI p HR 95% CI p
Age (reference: < 70) <0.01
70 NS NA NA
Age (continuous variable) <0.01
NA 1.03 [1.01; 1.04] NS
Number of metastatic sites at metastatic diagnosis
(reference: 1 site)
<0.01 <0.01 <0.01
2 sites 1.20 [1.10; 1.31] 1.21 [1.00; 1.48] 1.29 [1.16; 1.42]
3 sites or more 1.45 [1.31; 1.61] 1.55 [1.24; 1.94] 1.72 [1.54; 1.93]
Visceral metastatic disease (reference: none) (*) <0.01 <0.01 <0.01
If no time; varying effect: Global HR NA 1.35 [1.12; 1.63] NA
Time; varying effect:
Estimated HR at 1 year 1.47 [1.22; 1.76] NA 1.59 [1.30; 1.95]
Estimated HR at 3 years 1.71 [1.43; 2.05] NA 2.02 [1.65; 2.47]
Estimated HR at 5 years 2.00 [1.67; 2.40] NA 2.56 [2.09; 3.13]
ER/PgR status (reference: both ER; and PgR;) <0.01 NS
NSIf no time; varying effect, estimated average HR <0.01
Positive ER and/or PgR NA NA NA NA
Undetermined ER/PgR status NA NA NA NA
If time; varying effect, estimated HR at 1 year
Positive ER and/or PgR 0.92 [0.85; 0.99] 0.87 [0.80; 0.95]
Undetermined ER/PgR status 0.86 [0.58; 1.26] 0.78 [0.50; 1.22]
If time; varying effect, estimated HR at 3 years
Positive ER and/or PgR 1.13 [1.05; 1.22] 1.08 [1.00; 1.18]
Undetermined ER/PgR status 1.05 [0.71; 1.55] 0.97 [0.62; 1.51]
If time; varying effect, estimated HR at 5 years
Positive ER and/or PgR 1.39 [1.28; 1.50] 1.35 [1.24; 1.46]
Undetermined ER/PgR status 1.29 [0.88; 1.90] 1.20 [0.77; 1.87]
First-line treatment (vs chemotherapy þ anti;






If no time-varying effect: Estimated average HR
chemotherapy without anti-HER2 therapy (±endocrine therapy) NA NA NA
anti-HER2 therapy alone or endocrine therapy alone or both NA NA NA
At 1 year
chemotherapy without anti-HER2 therapy (±endocrine therapy) 1.93 [1.67; 2.23] 1.68 [1.41; 2.00]
anti-HER2 therapy alone or endocrine therapy alone or both 1.75 [1.51; 2.03] 0.64 [0.49; 0.84]
At 3 years
chemotherapy without anti-HER2 therapy (±endocrine therapy) 1.17 [1.01; 1.36] 1.29 [1.08; 1.54]
anti-HER2 therapy alone or endocrine therapy alone or both 1.06 [0.92; 1.23] 0.49 [0.38; 0.64]
At 5 years
chemotherapy without anti; HER2 therapy (±endocrine therapy) 0.71 [0.62; 0.83] 0.99 [0.83; 1.18]
anti-HER2 therapy alone or endocrine therapy alone or both 0.65 [0.56; 0.75] 0.38 [0.29; 0.49]
MFI (months) (reference: < 6 months) <0.01 <0.01
6e24 months 2.10 [1.87; 2.35] 1.71 [1.33; 2.23] 2.42 [2.14; 2.74] <0.01
24 months and more 1.46 [1.35; 1.58] 1.09 [0.91; 1.29] 1.43 [1.31; 1.56]
Center size (number of patients/site) (reference: < 700 patients) <0.01 <0.01
700 to 1399 patients 0.83 [0.71; 0.98] NS 0.80 [0.68; 0.95]




MFI: Metastasis free interval.
NS: Not significant.
NA: Not applicable.
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developed and personalized geriatric assessment when frailty is
suggested, has become a mandatory and helpful strategy.
Although combinationwith chemotherapy has been established
as the standard use [27,28], older patients are at increased risk of
treatment-induced toxicity and require important strategy adjust-
ments [19]. Even in fit ones who may be treated as younger ones,
there should be no decreased attention regarding potential toxicity.
For those who are frail or unfit, less toxic schedules and combina-
tions are recommended. For example, the EORTC conducted an
open label randomized phase II trial in first line HER2þ MBC in144older and frail patients [28]. Seventeen percent of patients had a G8
 14, suggesting potential frailty. Patients were randomized be-
tween dual anti-HER2 blockade (pertuzumabþ trastuzumab) alone
or with metronomic cyclophosphamide, reaching a median PFS of
5.6 months (95% CI 30.2e60.7) and 12.7 months (6.7e24.8),
respectively, providing an attractive alternative to the standard
combination of dual blockade with taxanes. The TANDEM trial also
investigated successfully trastuzumab with endocrine therapy in
luminal HER2þ post-menopausal women with MBC [29]. Most
recently, the PERTAIN trial, with a median PFS of 27 months in the
group of patients who received aromatase inhibitors with
M. Annonay, L. Gauquelin, R. Geiss et al. The Breast 60 (2021) 138e146pertuzumab and trastuzumab, highlights that some patients may
benefit from this combination, without chemotherapy [30].
The major strength of our work is the size of the cohort, which
includes all HER2þ MBC 70þ with no age limitations nor selection
based on multimorbidities, making it more representative of daily
clinical practice.
However, our study has also major limitations. First, due to
missing data, we could not assess relative BC survival to take into
account competing risks for death. Furthermore, older patients
treated in comprehensive cancer centers may not be representative
of all patients, limiting extrapolation to other institutions, because
they tend to have less comorbidities and a higher socio economic
level than those referred to smaller local clinics and hospitals [31].
Other important limitations are due to the retrospective nature
of our cohort. Indicators of frailty like the screening tool G8, PS,
comorbidities or geriatric assessment, which provide prognostic
information in older populations with or without cancer, were
missing. Assessment of treatment safety was not available. We also
could not eliminate confounding factors like patient's choice who
may have influenced treatment decision. Although it would be of
interest, the number of patients aged >70 years did not allow
subgroup analyses by age groups.
Finally, the finding that the large size of the treating centre
(evaluated though the number of patients accrued in the cohort,
which is fully correlated to the total patients’ load of the center) had
a protective effect in the whole or younger population but not in
the older one is counterintuitive. Larger institutions have generally
higher resources to contract geriatricians to help tailoring treat-
ments in older patients, unless skewed or selected patients re-
cruitments create uneven access to these. This requires further
exploration and may reflect a different patient profile within larger
centers. Of note, secondary referrals are much more frequent in
bigger centers, but such patients are excluded from ESME and this
would not affect our results based on first-line treatments.
5. Conclusion
In this real world cohort, only 65% of women 70þ received
standard first-line treatment defined as chemotherapy with anti-
HER2 therapy, with or without endocrine therapy. Older women
were less likely to receive standard therapy compared with their
younger counterparts. These treatment differences were associated
with worse PFS and OS, although a causal relationship cannot
strictly be demonstrated. Given the lack of information on geriatric
assessment (e.g. general health status, functional status, comor-
bidity, etc.), confounding factors and usual selection biases cannot
be ruled out. These results stress the importance to study older
populations with specific approaches, not based on the usual
transfer of those developed in younger ones, in order to avoid under
and overtreatments.
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